NEW YORK, NY / ACCESSWIRE / November 22, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.
Amarin Corporation Plc (NASDAQ:AMRN)
CONTACT JAKUBOWITZ ABOUT AMRN:
https://claimyourloss.com/securities/amarin-corporation-plc-loss-submission-form/?id=21438&from=1
Class Period : December 5, 2018 - June 21, 2021
Lead Plaintiff Deadline : December 23, 2021
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) there was an increasingly high risk that certain of Amarin's patents would be invalidated; (ii) once the District Court invalidated certain of Amarin's patents, there was little to no chance of reversing that ruling; (iii) the Company's litigation was preventing it from effectuating a successful takeover; (iv) Defendants were downplaying the true threat the ongoing abbreviated new drug application litigation posed to the Company's business and future prospects; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.
Camber Energy, Inc. (NYSE:CEI)
CONTACT JAKUBOWITZ ABOUT CEI:
https://claimyourloss.com/securities/camber-energy-inc-loss-submission-form/?id=21438&from=1
Class Period : February 18, 2021 - October 4, 2021
Lead Plaintiff Deadline : December 28, 2021
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) Camber overstated the financial and business prospects of Viking as well as the combined company post merger; (ii) Camber failed to apprise investors of, and/or downplayed, the fact that its acquisition of a controlling interest in Viking would exacerbate the Company's delinquent financial statements and listing obligations with the NYSE; (iii) an institutional investor was diluting Camber's shares at a significant rate following the Company's July 12, 2021 update regarding the number of its shares of common stock issued and outstanding; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
Silverback Therapeutics, Inc. (NASDAQ:SBTX)
CONTACT JAKUBOWITZ ABOUT SBTX:
https://claimyourloss.com/securities/silverback-therapeutics-inc-loss-submission-form/?id=21438&from=1
This lawsuit is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired: (a) Silverback common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Company's initial public offering conducted on or about December 3, 2020 and/or (b) Silverback securities between December 3, 2020 and September 10, 2021, both dates inclusive.
Lead Plaintiff Deadline : January 4, 2022
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) Silverback's lead product candidate SBT6050, which is in a Phase I/Ib clinical trial, a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody that targets tumors, such as breast, gastric, and non-small cell lung cancers, was less effective than the Company had represented to investors; (ii) accordingly, the Company had overstated SBT6050's commercial and/or clinical prospects; and (iii) as a result, the Offering Documents and Defendants' public statements throughout the Class Period were materially false and/or misleading and failed to state information required to be stated therein.
Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887
SOURCE: Jakubowitz Law
View source version on accesswire.com:
https://www.accesswire.com/674053/LAWSUITS-FILED-AGAINST-AMRN-CEI-and-SBTX--JAKUBOWITZ-LAW-PURSUES-SHAREHOLDERS-CLAIMS